258 related articles for article (PubMed ID: 12933590)
21. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.
Rocha V; Labopin M; Sanz G; Arcese W; Schwerdtfeger R; Bosi A; Jacobsen N; Ruutu T; de Lima M; Finke J; Frassoni F; Gluckman E; ;
N Engl J Med; 2004 Nov; 351(22):2276-85. PubMed ID: 15564544
[TBL] [Abstract][Full Text] [Related]
22. Long-Term Impact of Cytomegalovirus Serologic Status on Lung Transplantation in the United States.
Kurihara C; Fernandez R; Safaeinili N; Akbarpour M; Wu Q; Budinger GRS; Bharat A
Ann Thorac Surg; 2019 Apr; 107(4):1046-1052. PubMed ID: 30476471
[TBL] [Abstract][Full Text] [Related]
23. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study.
Eapen M; Brazauskas R; Walters MC; Bernaudin F; Bo-Subait K; Fitzhugh CD; Hankins JS; Kanter J; Meerpohl JJ; Bolaños-Meade J; Panepinto JA; Rondelli D; Shenoy S; Williamson J; Woolford TL; Gluckman E; Wagner JE; Tisdale JF
Lancet Haematol; 2019 Nov; 6(11):e585-e596. PubMed ID: 31495699
[TBL] [Abstract][Full Text] [Related]
24. Factors influencing cytomegalovirus seropositivity in stem cell transplant patients and donors.
Ljungman P; Brandan R
Haematologica; 2007 Aug; 92(8):1139-42. PubMed ID: 17650447
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for cytomegalovirus reactivation after liver transplantation: can pre-transplant cytomegalovirus antibody titers predict outcome?
Bruminhent J; Thongprayoon C; Dierkhising RA; Kremers WK; Theel ES; Razonable RR
Liver Transpl; 2015 Apr; 21(4):539-46. PubMed ID: 25597303
[TBL] [Abstract][Full Text] [Related]
26. Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants.
Nachbaur D; Clausen J; Kircher B
Eur J Haematol; 2006 May; 76(5):414-9. PubMed ID: 16480430
[TBL] [Abstract][Full Text] [Related]
27. Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation.
Junghanss C; Storb R; Maris MB; Carter RA; Sandmaier BM; Maloney DG; McSweeney PA; Corey L; Boeckh M
Br J Haematol; 2003 Nov; 123(4):662-70. PubMed ID: 14616970
[TBL] [Abstract][Full Text] [Related]
28. Haploidentical
Brissot E; Labopin M; Ehninger G; Stelljes M; Brecht A; Ganser A; Tischer J; Kröger N; Afanasyev B; Finke J; Elmaagacli A; Einsele H; Mohty M; Nagler A
Haematologica; 2019 Mar; 104(3):524-532. PubMed ID: 30361416
[TBL] [Abstract][Full Text] [Related]
29. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes.
Dalle JH; Balduzzi A; Bader P; Lankester A; Yaniv I; Wachowiak J; Pieczonka A; Bierings M; Yesilipek A; Sedlaçek P; Ifversen M; Sufliarska S; Toporski J; Glogova E; Poetschger U; Peters C
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1848-1855. PubMed ID: 29772352
[TBL] [Abstract][Full Text] [Related]
31. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis.
Teira P; Battiwalla M; Ramanathan M; Barrett AJ; Ahn KW; Chen M; Green JS; Saad A; Antin JH; Savani BN; Lazarus HM; Seftel M; Saber W; Marks D; Aljurf M; Norkin M; Wingard JR; Lindemans CA; Boeckh M; Riches ML; Auletta JJ
Blood; 2016 May; 127(20):2427-38. PubMed ID: 26884374
[TBL] [Abstract][Full Text] [Related]
32. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
Boeckh M; Bowden RA; Storer B; Chao NJ; Spielberger R; Tierney DK; Gallez-Hawkins G; Cunningham T; Blume KG; Levitt D; Zaia JA
Biol Blood Marrow Transplant; 2001; 7(6):343-51. PubMed ID: 11464977
[TBL] [Abstract][Full Text] [Related]
33. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients.
Ljungman P; Aschan J; Lewensohn-Fuchs I; Carlens S; Larsson K; Lönnqvist B; Mattsson J; Sparrelid E; Winiarski J; Ringdén O
Transplantation; 1998 Nov; 66(10):1330-4. PubMed ID: 9846518
[TBL] [Abstract][Full Text] [Related]
34. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure.
Nakamura R; Battiwalla M; Solomon S; Follmann D; Chakrabarti S; Cortez K; Hensel N; Childs R; Barrett AJ
Biol Blood Marrow Transplant; 2004 Jan; 10(1):49-57. PubMed ID: 14752779
[TBL] [Abstract][Full Text] [Related]
35. Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT.
Cesaro S; Crocchiolo R; Tridello G; Knelange N; Van Lint MT; Koc Y; Ciceri F; Gülbas Z; Tischer J; Afanasyev B; Bruno B; Castagna L; Blaise D; Mohty M; Irrera G; Diez-Martin JL; Pierelli L; Pioltelli P; Arat M; Delia M; Fagioli F; Ehninger G; Aljurf M; Carella AM; Ozdogu H; Mikulska M; Ljungman P; Nagler A; Styczynski J
Bone Marrow Transplant; 2018 Apr; 53(4):422-430. PubMed ID: 29330396
[TBL] [Abstract][Full Text] [Related]
36. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders.
Chen C; Busson M; Rocha V; Appert ML; Lepage V; Dulphy N; Haas P; Socié G; Toubert A; Charron D; Loiseau P
Bone Marrow Transplant; 2006 Sep; 38(6):437-44. PubMed ID: 16892071
[TBL] [Abstract][Full Text] [Related]
37. Stem cell transplantation for chronic myeloid leukemia in children.
Cwynarski K; Roberts IA; Iacobelli S; van Biezen A; Brand R; Devergie A; Vossen JM; Aljurf M; Arcese W; Locatelli F; Dini G; Niethammer D; Niederwieser D; Apperley JF;
Blood; 2003 Aug; 102(4):1224-31. PubMed ID: 12714525
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.
Shouval R; Fein JA; Labopin M; Kröger N; Duarte RF; Bader P; Chabannon C; Kuball J; Basak GW; Dufour C; Galimard JE; Polge E; Lankester A; Montoto S; Snowden JA; Styczynski J; Yakoub-Agha I; Mohty M; Nagler A
Lancet Haematol; 2019 Nov; 6(11):e573-e584. PubMed ID: 31477550
[TBL] [Abstract][Full Text] [Related]
39. Specific donor HLA allotypes as predictors of cytomegalovirus disease risk in acute myeloid leukemia.
Min GJ; Kim HJ; Kim TG; Hyun YS; Hyun SJ; Baek IC; Yoon SY; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW
HLA; 2020 Oct; 96(4):445-455. PubMed ID: 32506817
[TBL] [Abstract][Full Text] [Related]
40. Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.
Liu LW; Yn A; Gao F; Olson M; Crain M; Abboud R; Westervelt P; Abboud C; Vij R; Stockerl-Goldstein K; Pusic I; Cashen AF; Schroeder MA
Transplant Cell Ther; 2022 Aug; 28(8):510.e1-510.e9. PubMed ID: 35598841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
